An intensely uncomfortable but rarely life-threatening syndrome following reduction of opioid use, marked by flu-like symptoms and severe craving.
Medically reviewed by
Dr. Mihaela G.
Opioid Withdrawal describes the intensely uncomfortable syndrome that develops after stopping or significantly reducing opioid use following sustained physical dependence. The symptom picture, often described as feeling like a severe flu combined with significant anxiety and physical agitation, is genuinely miserable, but, importantly, rarely medically dangerous in otherwise healthy adults, distinguishing it sharply from alcohol or sedative withdrawal, where serious medical complications including seizures are a real concern.
This distinction matters considerably for understanding the condition: opioid withdrawal’s primary risk isn’t a medical emergency in the way alcohol withdrawal can be. It’s relapse, and relapse during opioid withdrawal or shortly afterward carries its own significant danger given reduced tolerance, a connection that’s central to understanding why opioid withdrawal, despite not typically being life-threatening itself, deserves serious clinical attention and effective management.
The intensity of the discomfort is itself a major factor maintaining ongoing opioid use for many people; a substantial proportion of continued use, once dependence has developed, is driven less by pursuit of euphoria and more by a powerful desire to avoid withdrawal, a dynamic important to understand both for compassionate, accurate clinical care and for the person experiencing it.
Flu-like physical symptoms
Muscle aches, runny nose, watery eyes, yawning, sweating, and piloerection (“goosebumps,” historically the origin of the phrase “cold turkey”), reflecting the syndrome’s characteristic flu-like quality.
Gastrointestinal symptoms
Nausea, vomiting, diarrhea, and abdominal cramping, often among the most physically distressing features of the syndrome.
Autonomic and physical signs
Pupillary dilation, elevated heart rate and blood pressure, and fever, reflecting a rebound of the autonomic nervous system activity that opioids had been suppressing.
Psychological symptoms
Dysphoric mood, significant anxiety, irritability, and intense craving, often described as severe and central to the experience.
Timeline
Onset and duration vary by the specific opioid’s half-life; symptoms from shorter-acting opioids (like heroin) typically begin within 6-12 hours and peak around 1-3 days, while longer-acting opioids (like methadone) produce a delayed but more prolonged course.
⋅ Significant anxiety and irritability
⋅ Dysphoric, distressed mood
⋅ Intense craving, often a dominant feature of the experience
⋅ Restlessness and a felt inability to settle
⋅ Difficulty concentrating due to physical discomfort and distress
⋅ Persistent, often intense preoccupation with relieving the symptoms
⋅ Heightened sensitivity to discomfort more generally during this period
⋅ Impaired sleep affecting overall cognitive functioning
⋅ Muscle aches, sweating, runny nose, and watery eyes
⋅ Nausea, vomiting, diarrhea, and abdominal cramping
⋅ Pupillary dilation, elevated heart rate, and fever
⋅ Insomnia and significant physical restlessness
⋅ Significant restlessness and inability to settle or rest comfortably
⋅ Strong urge-driven behavior aimed at obtaining relief
⋅ Withdrawal from usual activities due to physical discomfort
⋅ Seeking medical attention given the severity and distress of symptoms
Opioid withdrawal occurs in nearly all individuals with established physical dependence on opioids who stop or significantly reduce use, making it one of the more universally experienced withdrawal syndromes among substances covered in this manual, once dependence has developed.
Severity and timeline vary based on the specific opioid used, the duration and intensity of use, and individual factors including overall health and any co-occurring medical conditions.
Comorbidity with anxiety disorders can intensify the subjective distress of withdrawal, given the significant overlap between withdrawal symptoms and anxiety symptoms, and pre-existing anxiety vulnerability may make the psychological component of withdrawal feel particularly overwhelming for some individuals.
Opioid withdrawal results from the sudden loss of opioid receptor activation in a nervous system that has adapted to its chronic presence, producing a pronounced rebound effect.
Locus coeruleus rebound is central to the underlying mechanism; this brainstem region, normally suppressed by opioid activity, becomes hyperactive once that suppression is removed, driving the surge in norepinephrine responsible for many of withdrawal’s characteristic autonomic symptoms, elevated heart rate, sweating, anxiety, and physical agitation.
Loss of opioid-mediated pain and gut motility suppression explains other prominent features; opioids normally suppress pain signaling and slow gastrointestinal motility, so their absence produces a rebound of both heightened pain sensitivity and significantly increased gut activity, contributing to the muscle aches and gastrointestinal symptoms characteristic of withdrawal.
The specific opioid’s half-life significantly shapes the timeline; shorter-acting opioids leave the system more quickly, producing a faster onset but typically shorter overall withdrawal course, while longer-acting opioids produce a delayed onset but a more protracted, sometimes more manageable, withdrawal experience.
Opioid Withdrawal is diagnosed based on cessation or reduction of opioid use after sustained, heavy use, or administration of an opioid antagonist after a period of opioid use, with three or more of the following developing within minutes to several days: dysphoric mood, nausea or vomiting, muscle aches, lacrimation or rhinorrhea, pupillary dilation, piloerection, sweating, diarrhea, yawning, fever, and insomnia. Symptoms cause significant distress or impairment and aren’t attributable to another medical condition or better explained by another mental disorder.
Differential diagnosis requires distinguishing opioid withdrawal from other conditions producing overlapping symptoms, including gastrointestinal illness, anxiety disorders, and withdrawal from other substances, though the characteristic combination of flu-like symptoms, gastrointestinal distress, and pupillary dilation, alongside a clear history of recent opioid cessation or reduction, generally provides a relatively clear clinical picture.
Opioid withdrawal management has well-established, effective treatment options, and managing it well matters considerably both for the person’s comfort and for supporting successful transition to longer-term treatment.
Medication-assisted withdrawal management
Buprenorphine can be used to manage withdrawal directly, often as a bridge to longer-term maintenance treatment, working by activating opioid receptors partially, easing withdrawal symptoms without producing the same degree of euphoria as full opioid agonists. Methadone can similarly be used in supervised settings for withdrawal management.
Symptom-specific supportive medications
Clonidine helps address the autonomic symptoms (elevated heart rate, sweating, anxiety) driven by the norepinephrine surge characteristic of withdrawal. Additional supportive medications can target specific symptoms including nausea, diarrhea, and muscle aches.
Transition to ongoing medication-based treatment
Given the strong evidence for medication-based treatment of opioid use disorder, managed withdrawal is ideally approached as a bridge toward starting buprenorphine or methadone maintenance, rather than withdrawal alone followed by unsupported abstinence, given how significantly this transition reduces relapse and overdose risk.
Addressing the relapse-overdose connection directly
Given that relapse following withdrawal carries genuine overdose danger due to reduced tolerance, ensuring access to naloxone and clear safety information is an essential part of comprehensive withdrawal management, regardless of whether someone successfully transitions to maintenance treatment or not.
Seek medical support for withdrawal management rather than trying to manage severe symptoms entirely alone. Medications like buprenorphine, methadone, and clonidine can meaningfully ease the discomfort and support a safer, more successful transition.
Strongly consider transitioning directly into medication-based maintenance treatment, rather than withdrawal followed by unsupported abstinence. This is the approach with the strongest evidence for reducing relapse and overdose risk going forward.
Know that the worst physical symptoms are time-limited, even though the experience feels genuinely miserable while it’s happening. Most acute symptoms, particularly from shorter-acting opioids, begin to ease within several days, even though some symptoms, particularly sleep disturbance and craving, can persist longer.
Have naloxone access and a safety plan in place, especially if you’re not transitioning directly to maintenance medication. Given how significantly tolerance decreases during withdrawal, any return to use afterward carries genuine overdose risk that’s important to plan for.
Address comorbid anxiety directly, since this can significantly intensify the subjective distress of withdrawal. Support for the psychological dimension of withdrawal, alongside physical symptom management, supports a more complete, manageable experience.
The outlook for opioid withdrawal, in terms of the acute physical syndrome itself, is generally good; while genuinely uncomfortable, it’s rarely medically dangerous in otherwise healthy adults, and symptoms reliably resolve, typically within one to two weeks, depending on the specific opioid involved.
The primary risk connected to opioid withdrawal isn’t the syndrome itself but what happens afterward; without transition to effective ongoing treatment, relapse is common, and relapse following a period of reduced tolerance carries genuine, serious overdose danger.
With successful transition to medication-based maintenance treatment, following managed withdrawal, outcomes are considerably more favorable, both for sustained recovery and for meaningfully reducing the risk of fatal overdose going forward.
Seek medical support for withdrawal management if you’re stopping or reducing opioid use after a period of physical dependence, given how much medications like buprenorphine, methadone, and clonidine can ease the process.
Seek connection to ongoing, medication-based treatment as part of your withdrawal plan, rather than pursuing withdrawal in isolation, given the strong evidence supporting this approach for reducing future relapse and overdose risk.
Seek naloxone access and overdose safety planning regardless of your specific treatment path, given how significantly reduced tolerance after withdrawal increases danger if a relapse occurs.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
For most otherwise healthy adults, opioid withdrawal itself is not typically medically dangerous, unlike alcohol or sedative withdrawal, which can involve seizures and other serious complications. It is, however, intensely uncomfortable, often described as feeling like a severe flu combined with significant anxiety. The main danger connected to opioid withdrawal isn’t the syndrome itself, but the risk of overdose if relapse occurs afterward, given how significantly tolerance decreases during the withdrawal period.
Many of the most prominent withdrawal symptoms, muscle aches, runny nose, sweating, nausea, closely resemble flu symptoms because both involve similar underlying physiological processes, including autonomic nervous system activation and gastrointestinal effects. This is part of why opioid withdrawal is sometimes informally described this way, even though the underlying cause, opioid receptor adaptation rather than viral infection, is completely different.
Buprenorphine and methadone can be used to manage withdrawal directly, often as a bridge to longer-term maintenance treatment, while clonidine helps address autonomic symptoms like elevated heart rate and anxiety. Additional supportive medications can target specific symptoms like nausea or diarrhea. Managed withdrawal is most effective when approached as a transition toward ongoing medication-based treatment, rather than as a standalone process followed by unsupported abstinence.
Tolerance to opioids decreases significantly during withdrawal and the period of abstinence that follows. If someone relapses and uses an amount similar to what they used regularly before stopping, this can result in a dose far more dangerous than their body can now handle, significantly increasing overdose risk. This is one of the most important reasons why connecting withdrawal management to ongoing treatment, and ensuring naloxone access regardless, matters so much for safety.
Kosten, T. R., & George, T. P. (2002). The neurobiology of opioid dependence: implications for treatment. Science & Practice Perspectives, 1(1), 13–20. PubMed
Gowing, L., Farrell, M., Ali, R., & White, J. M. (2016). Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, (5), CD002024. PubMed
Gowing, L., Ali, R., & White, J. M. (2017). Buprenorphine for managing opioid withdrawal. Cochrane Database of Systematic Reviews, (2), CD002025. PubMed
Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S., & Gossop, M. (2003). Loss of tolerance and overdose mortality after inpatient opioid detoxification: follow up study. BMJ, 326(7396), 959–960. PubMed
Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259. PubMed
